Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02881047
Other study ID # UPCC 14613
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date November 11, 2013
Est. completion date August 19, 2016

Study information

Verified date April 2020
Source Abramson Cancer Center of the University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Graft versus host disease (GVHD) is a common complication of allogeneic stem cell transplant.Chronic GVHD is characterized by skin thickening and tightening. Advanced sclerosis can lead to reduced range of motion and incapacitating joint contractures. Once present, there are few therapeutic options. We will treat sclerosis and limb contractures with an ablative fractional laser, a device FDA-approved for scar treatment. This approach has successfully treated contracturesdue to burn scars.


Recruitment information / eligibility

Status Terminated
Enrollment 8
Est. completion date August 19, 2016
Est. primary completion date August 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects must be able to give informed consent

- All adult patients (18 years of age or older) Severe sclerotic skin changes of chronic graft versus host disease meeting a score of 3 on the NIH consensus criteria for organ scoring of chronic GVHD,

- a score defined by deep sclerotic features with hidebound skin which cannot be pinched together, resulting in impaired motion.

- According to the NIH criteria, the patient need not have widespread cutaneous GVHD; hidebound skin OR impaired mobility receive a score of 3 (highest score).

- Demonstrable range of motion limitations and joint contractures due to sclerotic GVHD across a specific joint / limb amenable to laser therapy must be present. - - Patients must note an inability to bend the joint (e.g. foot, wrist, elbow) freely which compromises the ability to perform specific tasks (e.g. walking up or down stairs, grabbing / making a fist, lifting or raising thearms over the head). As these functional limitations are by their nature subjective (and NIH scoring criteria are themselves subjective) determination of eligibility will be made by the investigator.

- ECOG Performance Status shall be 0-3

Exclusion Criteria:

- Persons unable to provide informed consent Pregnant or nursing women, or children under age 18

- Active infections such as herpes simplex virus (HSV) Acute, untreated medical problems such as poorly-controlled diabetes, decompensated heart failure, etc.

- There are no specific contraindications to use of the laser based on skin pigmentation, sun sensitivity, history of keloids, use of specific medications, etc.

- Appropriateness for trial entry will be determined on an individual basis by the study investigators.

- Patients with ECOG Performance Status 3 will be excluded.

- Patients with ANC 1500,PLT 50, or Hgb 8.0 will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CO2 Laser
Perform ablative fractional resurfacing using a 10,600nm carbon dioxide (CO2) laser targeted to thickened, sclerotic plaques causing range of motion limitation and contracture across joints.
Radiation:
Ultrasound
Patients will undergo ultrasound of the planned treatment site to measure skin thickness and blood flow via Doppler ultrasound.
Diagnostic Test:
Skin Biopsy
standard 4mm punch biopsy of the skin at the planned treatment site for histologic assessment of skin thickness and sclerosis.

Locations

Country Name City State
United States Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Abramson Cancer Center of the University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Who Show Improvement in Range of Motion, Flexion, and Extension Range of motion (flexion, extension, supination, pronation) of the target joint (measured in degrees, using a goniometer). 5 months from time point zero / baseline
Primary Number of Subjects With Evidence of Collagen Remodeling (Increased Dermal Echogenicity) Compared to Baseline Measurement of skin echogencity (brightness) in comparison with pre-therapy images of the same areas using high-resolution ultrasound. 3 months after final laser session (5 months after time zero / baseline)
Primary Number of Subjects Who Show Decrease in Skin Thickness and Sclerosis With Collagen Remodeling as Measured by Before and After Skin Biopsies Biopsy Trichcrome stain, collagen fiber number and thickness, Herovici stain, elastic fiber length, and dermal thickness. baseline and 3 months after final laser session